The University of Chicago Header Logo

Connection

Marina Chiara Garassino to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about Lung Neoplasms.
Marina Chiara Garassino
Connection Strength
20.109
Lung Neoplasms
  1. Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC. J Thorac Oncol. 2024 Jun; 19(6):877-882.
    View in: PubMed
    Score: 0.377
  2. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. 2024 Aug 20; 42(24):2860-2872.
    View in: PubMed
    Score: 0.377
  3. Neoadjuvant or Perioperative Approach in Lung Cancer. N Engl J Med. 2024 May 16; 390(19):1816-1818.
    View in: PubMed
    Score: 0.376
  4. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023 04 10; 41(11):1992-1998.
    View in: PubMed
    Score: 0.345
  5. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. ESMO Open. 2022 12; 7(6):100645.
    View in: PubMed
    Score: 0.340
  6. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022 12; 17(12):1415-1427.
    View in: PubMed
    Score: 0.333
  7. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 11; 23(7):e489-e499.
    View in: PubMed
    Score: 0.331
  8. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. Eur J Cancer. 2021 05; 149:235-248.
    View in: PubMed
    Score: 0.303
  9. Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. Immunotherapy. 2021 05; 13(7):621-631.
    View in: PubMed
    Score: 0.303
  10. Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Crit Rev Oncol Hematol. 2021 Apr; 160:103299.
    View in: PubMed
    Score: 0.302
  11. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncol. 2021 Apr; 17(10):1165-1184.
    View in: PubMed
    Score: 0.300
  12. Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events. J Thorac Oncol. 2021 02; 16(2):183-186.
    View in: PubMed
    Score: 0.299
  13. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. ESMO Open. 2021 02; 6(1):100034.
    View in: PubMed
    Score: 0.298
  14. To Continue or Not to Continue? That Is the Question. J Clin Oncol. 2020 11 20; 38(33):3830-3832.
    View in: PubMed
    Score: 0.292
  15. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer. 2020 09; 147:137-142.
    View in: PubMed
    Score: 0.287
  16. LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open. 2020 05; 5(3):e000748.
    View in: PubMed
    Score: 0.284
  17. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 03; 21(3):387-397.
    View in: PubMed
    Score: 0.280
  18. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019 May; 75:39-51.
    View in: PubMed
    Score: 0.263
  19. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. Tumour Biol. 2018 Nov; 40(11):1010428318815047.
    View in: PubMed
    Score: 0.256
  20. Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2018 09 13; 379(11):e18.
    View in: PubMed
    Score: 0.254
  21. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2019 02 01; 25(3):989-999.
    View in: PubMed
    Score: 0.254
  22. Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. J Thorac Oncol. 2018 08; 13(8):1146-1155.
    View in: PubMed
    Score: 0.247
  23. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 May 31; 378(22):2078-2092.
    View in: PubMed
    Score: 0.247
  24. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 04; 19(4):521-536.
    View in: PubMed
    Score: 0.245
  25. Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. Curr Drug Targets. 2017; 18(3):341-362.
    View in: PubMed
    Score: 0.226
  26. Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet. Tumori. 2016 Jun 02; 2016(3):223-5.
    View in: PubMed
    Score: 0.213
  27. Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol. 2016 Jun; 37(6):7047-57.
    View in: PubMed
    Score: 0.213
  28. Diagnosis and management of typical and atypical lung carcinoids. Crit Rev Oncol Hematol. 2016 Apr; 100:167-76.
    View in: PubMed
    Score: 0.212
  29. EGFR mutations and EGFR tyrosine kinase inhibitors. Lancet Oncol. 2015 Jul; 16(7):746-8.
    View in: PubMed
    Score: 0.202
  30. A lesson from vorinostat in pleural mesothelioma. Lancet Oncol. 2015 Apr; 16(4):359-60.
    View in: PubMed
    Score: 0.199
  31. Afatinib for lung cancer: let there be light? Lancet Oncol. 2014 Feb; 15(2):133-4.
    View in: PubMed
    Score: 0.184
  32. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013 Sep; 14(10):981-8.
    View in: PubMed
    Score: 0.178
  33. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev. 2014 Feb; 40(1):197-203.
    View in: PubMed
    Score: 0.177
  34. To target or not to target, that is the question. J Clin Oncol. 2013 Mar 20; 31(9):1254.
    View in: PubMed
    Score: 0.172
  35. Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin. J Clin Oncol. 2011 Oct 01; 29(28):3835-7; author reply 3837-9.
    View in: PubMed
    Score: 0.156
  36. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2011 Jan; 22(1):235-237.
    View in: PubMed
    Score: 0.149
  37. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer. 2011 Jun; 72(3):378-83.
    View in: PubMed
    Score: 0.147
  38. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2010 Nov; 70(2):119-28.
    View in: PubMed
    Score: 0.140
  39. Bevacizumab for non-small-cell lung cancer. N Engl J Med. 2007 Mar 29; 356(13):1373; author reply 1374-5.
    View in: PubMed
    Score: 0.115
  40. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. J Immunother Cancer. 2025 Feb 04; 13(2).
    View in: PubMed
    Score: 0.099
  41. Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review. Lung Cancer. 2025 Jan; 199:108051.
    View in: PubMed
    Score: 0.098
  42. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
    View in: PubMed
    Score: 0.097
  43. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024 Sep 26; 10(1):71.
    View in: PubMed
    Score: 0.096
  44. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Sep 28; 404(10459):1240-1252.
    View in: PubMed
    Score: 0.096
  45. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. 2025 Jan 20; 43(3):260-272.
    View in: PubMed
    Score: 0.096
  46. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
    View in: PubMed
    Score: 0.096
  47. Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer. 2024 Jul 25; 23(Suppl 1):1250.
    View in: PubMed
    Score: 0.095
  48. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30; 23(1):115.
    View in: PubMed
    Score: 0.094
  49. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial. Oncologist. 2024 May 03; 29(5):e690-e698.
    View in: PubMed
    Score: 0.094
  50. The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project. Cancer Med. 2024 May; 13(9):e7159.
    View in: PubMed
    Score: 0.094
  51. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024 Aug; 19(8):1228-1241.
    View in: PubMed
    Score: 0.093
  52. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024 Jul; 19(7):1108-1116.
    View in: PubMed
    Score: 0.093
  53. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 02 16; 30(4):824-835.
    View in: PubMed
    Score: 0.092
  54. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. J Exp Clin Cancer Res. 2024 Jan 02; 43(1):6.
    View in: PubMed
    Score: 0.092
  55. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). Lung Cancer. 2024 01; 187:107441.
    View in: PubMed
    Score: 0.091
  56. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. J Clin Oncol. 2024 Jan 10; 42(2):192-204.
    View in: PubMed
    Score: 0.091
  57. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B. Cell Rep Med. 2023 11 21; 4(11):101280.
    View in: PubMed
    Score: 0.091
  58. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023 12; 186:107418.
    View in: PubMed
    Score: 0.091
  59. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. Lung Cancer. 2023 12; 186:107417.
    View in: PubMed
    Score: 0.090
  60. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Eur J Cancer. 2023 12; 195:113404.
    View in: PubMed
    Score: 0.090
  61. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1260-1266.
    View in: PubMed
    Score: 0.089
  62. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. Clin Lung Cancer. 2023 11; 24(7):631-640.e2.
    View in: PubMed
    Score: 0.089
  63. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 09; 24(9):989-1001.
    View in: PubMed
    Score: 0.089
  64. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571.
    View in: PubMed
    Score: 0.089
  65. Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. J Clin Oncol. 2023 09 01; 41(25):4093-4096.
    View in: PubMed
    Score: 0.088
  66. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. J Immunother Cancer. 2023 06; 11(6).
    View in: PubMed
    Score: 0.088
  67. Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer. Int J Mol Sci. 2023 May 29; 24(11).
    View in: PubMed
    Score: 0.088
  68. STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines. J Thorac Oncol. 2023 08; 18(8):1070-1081.
    View in: PubMed
    Score: 0.087
  69. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). J Thorac Oncol. 2023 08; 18(8):1031-1041.
    View in: PubMed
    Score: 0.087
  70. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 06; 24(4):381-387.
    View in: PubMed
    Score: 0.086
  71. Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121.
    View in: PubMed
    Score: 0.086
  72. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol. 2023 02; 18(2):181-193.
    View in: PubMed
    Score: 0.084
  73. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. Front Immunol. 2022; 13:987639.
    View in: PubMed
    Score: 0.084
  74. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. J Thorac Oncol. 2022 09; 17(9):1122-1129.
    View in: PubMed
    Score: 0.082
  75. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncol. 2022 Jul; 18(23):2593-2604.
    View in: PubMed
    Score: 0.082
  76. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 09; 17(9):1086-1097.
    View in: PubMed
    Score: 0.082
  77. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer. 2022 08; 170:41-51.
    View in: PubMed
    Score: 0.082
  78. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126.
    View in: PubMed
    Score: 0.081
  79. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 04; 7(2):100408.
    View in: PubMed
    Score: 0.081
  80. Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? J Thorac Oncol. 2022 03; 17(3):e35-e38.
    View in: PubMed
    Score: 0.081
  81. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 04 20; 40(12):1301-1311.
    View in: PubMed
    Score: 0.080
  82. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022 05; 17(5):661-674.
    View in: PubMed
    Score: 0.080
  83. Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol. 2022 03 01; 40(7):710-718.
    View in: PubMed
    Score: 0.079
  84. Comprehensive metastatic ablation in advanced NSCLC through biology-guided radiotherapy - A path forward? Lung Cancer. 2021 12; 162:203-206.
    View in: PubMed
    Score: 0.079
  85. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. Lung Cancer. 2021 10; 160:152-165.
    View in: PubMed
    Score: 0.077
  86. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. 2021 11; 16(11):1883-1892.
    View in: PubMed
    Score: 0.077
  87. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. Clin Lung Cancer. 2022 01; 23(1):e17-e28.
    View in: PubMed
    Score: 0.077
  88. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021 09; 32(9):1101-1110.
    View in: PubMed
    Score: 0.077
  89. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 2021 07; 157:9-16.
    View in: PubMed
    Score: 0.076
  90. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. Eur J Cancer. 2021 06; 150:224-231.
    View in: PubMed
    Score: 0.076
  91. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021 07; 32(7):881-895.
    View in: PubMed
    Score: 0.076
  92. LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. J Thorac Oncol. 2021 08; 16(8):1298-1311.
    View in: PubMed
    Score: 0.076
  93. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. J Thorac Oncol. 2021 08; 16(8):1369-1378.
    View in: PubMed
    Score: 0.076
  94. Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunol Immunother. 2021 Sep; 70(9):2429-2438.
    View in: PubMed
    Score: 0.076
  95. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021 04; 9(4).
    View in: PubMed
    Score: 0.076
  96. First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report. J Thorac Oncol. 2021 05; 16(5):873-877.
    View in: PubMed
    Score: 0.076
  97. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021 03; 9(3).
    View in: PubMed
    Score: 0.075
  98. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clin Lung Cancer. 2021 07; 22(4):301-312.e8.
    View in: PubMed
    Score: 0.075
  99. Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients. Front Public Health. 2021; 9:622154.
    View in: PubMed
    Score: 0.075
  100. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021 05; 16(5):860-867.
    View in: PubMed
    Score: 0.075
  101. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.
    View in: PubMed
    Score: 0.075
  102. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021 02 20; 39(6):619-630.
    View in: PubMed
    Score: 0.075
  103. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer. 2021 02; 152:165-173.
    View in: PubMed
    Score: 0.074
  104. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 01; 22(1):51-65.
    View in: PubMed
    Score: 0.074
  105. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. J Exp Clin Cancer Res. 2020 Nov 09; 39(1):236.
    View in: PubMed
    Score: 0.074
  106. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. Lung Cancer. 2020 12; 150:123-131.
    View in: PubMed
    Score: 0.073
  107. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer. 2021 03; 22(2):e180-e192.
    View in: PubMed
    Score: 0.073
  108. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020 11 15; 126(22):4867-4877.
    View in: PubMed
    Score: 0.073
  109. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 2020 11; 149:46-52.
    View in: PubMed
    Score: 0.073
  110. Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. Clin Cancer Res. 2021 01 15; 27(2):492-503.
    View in: PubMed
    Score: 0.073
  111. ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? Thromb Res. 2020 10; 194:176-177.
    View in: PubMed
    Score: 0.072
  112. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab. Acta Oncol. 2020 Sep; 59(9):1058-1063.
    View in: PubMed
    Score: 0.072
  113. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.
    View in: PubMed
    Score: 0.071
  114. Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center. Lung Cancer. 2020 08; 146:66-69.
    View in: PubMed
    Score: 0.071
  115. Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. J Thorac Oncol. 2020 07; 15(7):1119-1136.
    View in: PubMed
    Score: 0.071
  116. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. Curr Oncol Rep. 2020 04 16; 22(5):41.
    View in: PubMed
    Score: 0.071
  117. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020 05; 130:155-167.
    View in: PubMed
    Score: 0.071
  118. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 05 10; 38(14):1505-1517.
    View in: PubMed
    Score: 0.070
  119. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clin Lung Cancer. 2020 09; 21(5):e456-e463.
    View in: PubMed
    Score: 0.070
  120. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. Clin Lung Cancer. 2020 09; 21(5):e337-e348.
    View in: PubMed
    Score: 0.070
  121. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. Lung Cancer. 2020 04; 142:70-79.
    View in: PubMed
    Score: 0.070
  122. Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report. Tumori. 2020 Dec; 106(6):NP41-NP45.
    View in: PubMed
    Score: 0.070
  123. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol. 2020 02; 31(2):310-317.
    View in: PubMed
    Score: 0.069
  124. LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. J Thorac Oncol. 2020 03; 15(3):360-370.
    View in: PubMed
    Score: 0.068
  125. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clin Lung Cancer. 2020 05; 21(3):232-237.
    View in: PubMed
    Score: 0.068
  126. Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways. Lung Cancer. 2020 01; 139:13-17.
    View in: PubMed
    Score: 0.068
  127. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. J Neurol. 2019 12; 266(12):3163-3166.
    View in: PubMed
    Score: 0.068
  128. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer. 2019 11; 137:38-42.
    View in: PubMed
    Score: 0.068
  129. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. Tumori. 2019 Dec; 105(6):NP57-NP62.
    View in: PubMed
    Score: 0.068
  130. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019 10; 20(10):1395-1408.
    View in: PubMed
    Score: 0.068
  131. Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncol. 2019 Aug; 15(23):2743-2757.
    View in: PubMed
    Score: 0.067
  132. The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. Clin Lung Cancer. 2019 11; 20(6):e652-e660.
    View in: PubMed
    Score: 0.067
  133. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. J Thorac Oncol. 2019 08; 14(8):1390-1399.
    View in: PubMed
    Score: 0.066
  134. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer. 2019 06; 132:72-78.
    View in: PubMed
    Score: 0.066
  135. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. Lung Cancer. 2019 06; 132:17-23.
    View in: PubMed
    Score: 0.066
  136. BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience. J Thorac Oncol. 2019 03; 14(3):e57-e59.
    View in: PubMed
    Score: 0.065
  137. Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. BMJ Open. 2019 02 15; 9(2):e025483.
    View in: PubMed
    Score: 0.065
  138. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol. 2019 02 01; 30(2):161-165.
    View in: PubMed
    Score: 0.065
  139. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019 03; 129:35-40.
    View in: PubMed
    Score: 0.065
  140. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur J Cancer. 2019 02; 108:120-128.
    View in: PubMed
    Score: 0.065
  141. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clin Cancer Res. 2019 04 01; 25(7):2166-2173.
    View in: PubMed
    Score: 0.065
  142. Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Clin Lung Cancer. 2019 05; 20(3):e413-e417.
    View in: PubMed
    Score: 0.065
  143. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. J Exp Clin Cancer Res. 2018 Dec 04; 37(1):302.
    View in: PubMed
    Score: 0.064
  144. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. Target Oncol. 2018 12; 13(6):795-800.
    View in: PubMed
    Score: 0.064
  145. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018 11; 19(11):1468-1479.
    View in: PubMed
    Score: 0.064
  146. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. J Thorac Oncol. 2018 11; 13(11):1692-1704.
    View in: PubMed
    Score: 0.063
  147. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene. 2018 12; 37(50):6463-6476.
    View in: PubMed
    Score: 0.063
  148. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018 09 10; 36(26):2702-2709.
    View in: PubMed
    Score: 0.063
  149. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018 04 01; 29(4):959-965.
    View in: PubMed
    Score: 0.061
  150. Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. Eur Respir J. 2018 02; 51(2).
    View in: PubMed
    Score: 0.061
  151. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Sci Rep. 2018 01 17; 8(1):948.
    View in: PubMed
    Score: 0.061
  152. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. Handb Exp Pharmacol. 2018; 249:63-89.
    View in: PubMed
    Score: 0.060
  153. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. Lung Cancer. 2018 01; 115:135-142.
    View in: PubMed
    Score: 0.060
  154. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20; 35(24):2781-2789.
    View in: PubMed
    Score: 0.058
  155. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. Sci Rep. 2016 12 14; 6:39217.
    View in: PubMed
    Score: 0.056
  156. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 02 16; 376(7):629-640.
    View in: PubMed
    Score: 0.056
  157. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. Respir Res. 2016 08 25; 17(1):105.
    View in: PubMed
    Score: 0.055
  158. Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? Cancer Treat Rev. 2016 Jul; 48:8-19.
    View in: PubMed
    Score: 0.054
  159. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. Virchows Arch. 2016 Jun; 468(6):651-62.
    View in: PubMed
    Score: 0.054
  160. G48A, a New KRAS Mutation Found in Lung Adenocarcinoma. J Thorac Oncol. 2016 07; 11(7):1170-5.
    View in: PubMed
    Score: 0.054
  161. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Sci Rep. 2015 Nov 17; 5:16331.
    View in: PubMed
    Score: 0.052
  162. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. J Thorac Oncol. 2015 Nov; 10(11):1560-9.
    View in: PubMed
    Score: 0.052
  163. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget. 2015 Oct 20; 6(32):34014-22.
    View in: PubMed
    Score: 0.052
  164. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? Tumori. 2016 Jan-Feb; 102(1):18-30.
    View in: PubMed
    Score: 0.052
  165. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget. 2015 Oct 06; 6(30):30072-87.
    View in: PubMed
    Score: 0.052
  166. Challenging Lung Carcinoma with Coexistent ?Np63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. J Thorac Oncol. 2015 Oct; 10(10):1500-2.
    View in: PubMed
    Score: 0.052
  167. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Ann Oncol. 2015 Oct; 26(10):2079-84.
    View in: PubMed
    Score: 0.051
  168. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35.
    View in: PubMed
    Score: 0.051
  169. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Crit Rev Oncol Hematol. 2015 May; 94(2):213-27.
    View in: PubMed
    Score: 0.049
  170. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014 Mar; 9(3):390-6.
    View in: PubMed
    Score: 0.046
  171. Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations? J Clin Oncol. 2014 Mar 10; 32(8):859-63.
    View in: PubMed
    Score: 0.046
  172. Across the universe of K-RAS mutations in non-small-cell-lung cancer. Curr Pharm Des. 2014; 20(24):3933-43.
    View in: PubMed
    Score: 0.046
  173. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. Int J Surg Pathol. 2014 Apr; 22(2):136-48.
    View in: PubMed
    Score: 0.046
  174. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 2014 Feb; 89(2):284-99.
    View in: PubMed
    Score: 0.046
  175. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. J Thorac Oncol. 2013 Dec; 8(12):e105-6.
    View in: PubMed
    Score: 0.046
  176. The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. Cancer Treat Rev. 2014 May; 40(4):485-94.
    View in: PubMed
    Score: 0.045
  177. ?Np63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol. 2013 Jun; 21(3):229-39.
    View in: PubMed
    Score: 0.043
  178. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer. 2012 Sep; 77(3):507-14.
    View in: PubMed
    Score: 0.041
  179. Maintenance therapy in NSCLC: why? To whom? Which agent? J Exp Clin Cancer Res. 2011 May 06; 30:50.
    View in: PubMed
    Score: 0.038
  180. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. Clin Lung Cancer. 2011 Mar; 12(2):138-41.
    View in: PubMed
    Score: 0.038
  181. Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water? J Clin Oncol. 2010 Sep 20; 28(27):e467; author reply e468.
    View in: PubMed
    Score: 0.036
  182. Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res. 2009 Jul; 29(7):2691-701.
    View in: PubMed
    Score: 0.034
  183. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69.
    View in: PubMed
    Score: 0.015
  184. Predicting response of molecular targeted therapies: a still possible challenge? Ann Oncol. 2008 May; 19(5):829-30.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.